Spontaneous antibodies against Engrailed-2 (EN2) protein in patients with prostate cancer
Spontaneous antibodies against Engrailed-2 (EN2) protein in patients with prostate cancer
We reported the expression of the homeodomain-containing transcription factor Engrailed-2 (EN2) in prostate cancer and showed that the presence of EN2 protein in the urine was highly predictive of prostate cancer. This study aimed to determine whether patients with prostate cancer have EN2 autoantibodies, what the prevalence of these antibodies is and whether they are associated with disease stage. The spontaneous immunoglobulin (Ig)G immune response against EN2 and for comparison the tumour antigen New York Esophageal Squamous Cell Carcinoma 1 (NY-ESO-1), were tested by enzyme-linked immunosorbent assay (ELISA) in three different cohorts of prostate cancer patients as well as a group of men genetically predisposed to prostate cancer. Thirty-two of 353 (9·1%) of the SUN cohort representing all stages of prostate cancer demonstrated EN2 IgG responses, 12 of 107 patients (11·2%) in the advanced prostate cancer patients showed responses, while only four of 121 patients (3·3%) with castrate-resistant prostate cancer showed EN2 autoantibodies. No significant responses were found in the predisposed group. Anti-EN2 IgG responses were significantly higher in patients with prostate cancer compared to healthy control males and similarly prevalent to anti-NY-ESO-1 responses. While EN2 autoantibodies are not a useful diagnostic or monitoring tool, EN2 immunogenicity provides the rationale to pursue studies using EN2 as an immunotherapeutic target.
428-438
Annels, N.E.
8804eded-b7b9-4673-8aab-497b7d83c0de
Simpson, G.R.
eb51f990-05a7-4f9f-9cc7-da66c920db80
Denyer, M.
53fb3b2a-d1ad-47c5-bfad-f3afcd6b9a7d
McGrath, S.E.
62554027-f603-4510-9d99-852a2f120ee6
Falgari, G.
29bd6769-ee44-4e8c-a0e9-d7ed5b65d862
Killick, E.
333a1592-1d5f-42de-89d2-48a4e07fe2cf
Eeles, R.
c7ae2359-6f49-4f42-88f8-a241570f9d4f
Stebbing, J.
6136e559-1fcd-4f90-87d4-563302f8d127
Pchejetski, D.
df19c048-fdaa-4540-99dd-39e4b404298a
Cutress, R.
68ae4f86-e8cf-411f-a335-cdba51797406
Murray, N.
07091b97-fea7-483e-953d-64bc89b3ee96
Michael, A.
47cf9826-08c4-4cff-9c01-be6dd055f1d7
Pandha, H.
46b92aaf-f535-430f-89b4-be1f4f1d5ec1
August 2014
Annels, N.E.
8804eded-b7b9-4673-8aab-497b7d83c0de
Simpson, G.R.
eb51f990-05a7-4f9f-9cc7-da66c920db80
Denyer, M.
53fb3b2a-d1ad-47c5-bfad-f3afcd6b9a7d
McGrath, S.E.
62554027-f603-4510-9d99-852a2f120ee6
Falgari, G.
29bd6769-ee44-4e8c-a0e9-d7ed5b65d862
Killick, E.
333a1592-1d5f-42de-89d2-48a4e07fe2cf
Eeles, R.
c7ae2359-6f49-4f42-88f8-a241570f9d4f
Stebbing, J.
6136e559-1fcd-4f90-87d4-563302f8d127
Pchejetski, D.
df19c048-fdaa-4540-99dd-39e4b404298a
Cutress, R.
68ae4f86-e8cf-411f-a335-cdba51797406
Murray, N.
07091b97-fea7-483e-953d-64bc89b3ee96
Michael, A.
47cf9826-08c4-4cff-9c01-be6dd055f1d7
Pandha, H.
46b92aaf-f535-430f-89b4-be1f4f1d5ec1
Annels, N.E., Simpson, G.R., Denyer, M., McGrath, S.E., Falgari, G., Killick, E., Eeles, R., Stebbing, J., Pchejetski, D., Cutress, R., Murray, N., Michael, A. and Pandha, H.
(2014)
Spontaneous antibodies against Engrailed-2 (EN2) protein in patients with prostate cancer.
Clinical and Experimental Immunology, 177 (2), .
(doi:10.1111/cei.12332).
(PMID:24654775)
Abstract
We reported the expression of the homeodomain-containing transcription factor Engrailed-2 (EN2) in prostate cancer and showed that the presence of EN2 protein in the urine was highly predictive of prostate cancer. This study aimed to determine whether patients with prostate cancer have EN2 autoantibodies, what the prevalence of these antibodies is and whether they are associated with disease stage. The spontaneous immunoglobulin (Ig)G immune response against EN2 and for comparison the tumour antigen New York Esophageal Squamous Cell Carcinoma 1 (NY-ESO-1), were tested by enzyme-linked immunosorbent assay (ELISA) in three different cohorts of prostate cancer patients as well as a group of men genetically predisposed to prostate cancer. Thirty-two of 353 (9·1%) of the SUN cohort representing all stages of prostate cancer demonstrated EN2 IgG responses, 12 of 107 patients (11·2%) in the advanced prostate cancer patients showed responses, while only four of 121 patients (3·3%) with castrate-resistant prostate cancer showed EN2 autoantibodies. No significant responses were found in the predisposed group. Anti-EN2 IgG responses were significantly higher in patients with prostate cancer compared to healthy control males and similarly prevalent to anti-NY-ESO-1 responses. While EN2 autoantibodies are not a useful diagnostic or monitoring tool, EN2 immunogenicity provides the rationale to pursue studies using EN2 as an immunotherapeutic target.
This record has no associated files available for download.
More information
Published date: August 2014
Organisations:
Cancer Sciences
Identifiers
Local EPrints ID: 368060
URI: http://eprints.soton.ac.uk/id/eprint/368060
ISSN: 0009-9104
PURE UUID: 6ce80ff2-11b2-459e-b638-71722e5750ce
Catalogue record
Date deposited: 28 Aug 2014 10:25
Last modified: 14 Mar 2024 17:41
Export record
Altmetrics
Contributors
Author:
N.E. Annels
Author:
G.R. Simpson
Author:
M. Denyer
Author:
S.E. McGrath
Author:
G. Falgari
Author:
E. Killick
Author:
R. Eeles
Author:
J. Stebbing
Author:
D. Pchejetski
Author:
N. Murray
Author:
A. Michael
Author:
H. Pandha
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics